Pacira BioSciences Inc (NASDAQ: PCRX) has reported E.P.S. of $0.54 for its fourth fiscal quarter (ending December 31) versus $-0.22 for the same period a year ago. This performance was $-0.31 short of the consensus estimate of $0.85. For the latest four quarters through December 31, E.P.S. were $0.91 compared to $0.35 a year ago — an increase of 160%.
Recent Price Action
Pacira BioSciences Inc (NASDAQ: PCRX) stock closed at $29.72 on 2/29/24 after a slight decline of -0.6%. Moreover, trading volume in this decline was unusually high at 154% of normal. Relative to the market the stock has been weak over the last nine months but is unchanged during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to exceed the cost of capital, PCRX is expected to continue to be an important Value Builder.
Pacira BioSciences has a current Value Trend Rating of D (Negative). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Pacira BioSciences has a good Appreciation Score of 70 but a very low Power Rating of 13, resulting in the Negative Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment